Literature DB >> 26433822

Evolving treatment options for melanoma brain metastases.

Thankamma Ajithkumar1, Christine Parkinson2, Kate Fife2, Pippa Corrie2, Sarah Jefferies2.   

Abstract

Melanoma is a leading cause of lost productivity due to premature cancer mortality. Melanoma frequently spreads to the brain and is associated with rapid deterioration in quality and quantity of life. Until now, treatment options have been restricted to surgery and radiotherapy, although neither modality has been well studied in clinical trials. However, the new immune checkpoint inhibitors and molecularly targeted agents that have been introduced for treatment of metastatic melanoma are active against brain metastases and offer new opportunities to improve disease outcomes. New challenges arise, including how to integrate or sequence multiple treatment modalities, and current practice varies widely. In this Review, we summarise evidence for the treatment of melanoma brain metastases, and discuss the rationale and evidence for combination modalities, highlighting areas for future research.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26433822     DOI: 10.1016/S1470-2045(15)00141-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  31 in total

1.  Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma.

Authors:  Davide Franceschini; Ciro Franzese; Fiorenza De Rose; Pierina Navarria; Giuseppe R D'Agostino; Tiziana Comito; Angelo Tozzi; Maria C Tronconi; Lorenza Di Guardo; Michele Del Vecchio; Marta Scorsetti
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

2.  Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway.

Authors:  Xiangjun Chen; Hao Dong; Sha Liu; Li Yu; Dexiong Yan; Xingwei Yao; Weijing Sun; Dezhi Han; Guozhen Gao
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

3.  Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases.

Authors:  Giuseppe Minniti; Sergio Paolini; Giancarlo D'Andrea; Gaetano Lanzetta; Francesco Cicone; Veronica Confaloni; Alessandro Bozzao; Vincenzo Esposito; Mattia Osti
Journal:  J Neurooncol       Date:  2017-03-04       Impact factor: 4.130

Review 4.  A Blazing Landscape: Neuroinflammation Shapes Brain Metastasis.

Authors:  Hila Doron; Tobias Pukrop; Neta Erez
Journal:  Cancer Res       Date:  2019-01-24       Impact factor: 12.701

Review 5.  Current chemotherapeutic regimens for brain metastases treatment.

Authors:  Joo Yeon Nam; Barbara J O'Brien
Journal:  Clin Exp Metastasis       Date:  2017-09-16       Impact factor: 5.150

6.  Challenges in the delivery of therapies to melanoma brain metastases.

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Brynna-Wilken Resman; Karen E Parrish; Svetomir N Markovic; Jann N Sarkaria; William F Elmquist
Journal:  Curr Pharmacol Rep       Date:  2016-11-09

Review 7.  The Treatment of Melanoma Brain Metastases.

Authors:  Nour Kibbi; Harriet Kluger
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

Review 8.  [Melanoma brain metastases : Treatment options].

Authors:  R Rauschenberg; G Tabatabai; E G C Troost; M Garzarolli; S Beissert; F Meier
Journal:  Hautarzt       Date:  2016-07       Impact factor: 0.751

Review 9.  Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Authors:  Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2016-10-22       Impact factor: 4.693

10.  Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.

Authors:  David Taggart; Tereza Andreou; Karen J Scott; Jennifer Williams; Nora Rippaus; Rebecca J Brownlie; Elizabeth J Ilett; Robert J Salmond; Alan Melcher; Mihaela Lorger
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.